Proteus, Otsuka expand their digital medicine collaboration with five-year, $88M deal
As the Abilify MyCite platform nears a full rollout, the companies said they are looking forward to employing the technology toward additional mental health therapies. (Source: mobihealthnews)
Source: mobihealthnews - October 15, 2018 Category: Information Technology Source Type: news
Otsuka, Magellan Health announce plans for US rollout of Abilify MyCite
The two companies are planning a limited initial deployment to gather additional real-world data before a wider release. (Source: mobihealthnews)
Source: mobihealthnews - August 30, 2018 Category: Information Technology Source Type: news
The Line Between Drugs and Devices Continues to Blur
Otsuka America Pharmaceutical has signed a collaboration agreement with Magellan Health designed to facilitate access to the first drug-device combination product approved by FDA to track drug ingestion. The agreement creates an opportunity for doctors and adult patients to gather experience in a real-world setting with the Abilify Mycite System, Princeton, NJ-based Otsuka said on Thursday.
The Abilify Mycite System is the perfect example of how the line between pharma and medtech continues to blur, which isn't necessarily a bad thing. The product is comprised of Otsuka's oral aripiprazole tablets embedded with...
Source: MDDI - August 30, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Digital Health Source Type: news
Otsuka inks collab deal to bring Abilify Mycite drug-device combo to US
Otsuka Pharmaceutical (TYO:4578) said today it inked a collaborative deal with health management group Magellan Health to distribute its drug-device combo Abilify Mycite in the US.
The Tokyo-based pharmaceutical company touted the Abilify Mycite system as the first FDA-approved drug-device combo designed to track drug ingestion, and said that the tracking data will be integrated into Magellan Health’s mental health provider network.
Read the whole story on our sister site, Drug Delivery Business News
The post Otsuka inks collab deal to bring Abilify Mycite drug-device combo to US appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 30, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Distribution Drug-Device Combinations Neurological Otsuka Holdings Source Type: news
Aristada Initio (Aripiprazole Lauroxil Injectable Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 24, 2018 Category: Drugs & Pharmacology Source Type: news
Aristada Initio (Aripiprazole Lauroxil Injectable Suspension) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 19, 2018 Category: Drugs & Pharmacology Source Type: news
FDA Approves Aristada Initio (aripiprazole lauroxil) for the Initiation of Aristada for Schizophrenia
DUBLIN, July 2, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved Aristada Initio (aripiprazole lauroxil) for the initiation of Aristada (aripiprazole lauroxil), a... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 2, 2018 Category: Drugs & Pharmacology Source Type: news
FDA Clears'Day One' Aristada Regimen for Treating Schizophrenia FDA Clears'Day One' Aristada Regimen for Treating Schizophrenia
The FDA has cleared an extended-release injectable version of aripiprazole lauroxil, making it the ' first and only long-acting atypical antipsychotic that can be initiated on day one, ' say researchers.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 2, 2018 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news
FDA OK's 1-Day Initiation for Long-Acting Injectable Schizophrenia Tx
(MedPage Today) -- May replace previous 21-day initiation regimen onto aripiprazole lauroxil (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 2, 2018 Category: American Health Source Type: news
Aripiprazole-induced Sleep-related Eating Disorder Aripiprazole-induced Sleep-related Eating Disorder
This case of sleep-related eating disorder in a patient taking aripiprazole for depression suggests that this disorder should be considered as a potential side effect of this drug.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 20, 2018 Category: Consumer Health News Tags: Psychiatry Journal Article Source Type: news
Aripiprazole Tablets (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - June 5, 2018 Category: Drugs & Pharmacology Source Type: news
Antipsychotic May Fuel Urge to Gamble Antipsychotic May Fuel Urge to Gamble
An updated literature review provides more evidence of an association between gambling disorder and the second-generation atypical antipsychotic aripiprazole.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 15, 2018 Category: Consumer Health News Tags: Psychiatry News Source Type: news
One-Day Injectable Aripiprazole Tx Passes Test
(MedPage Today) -- Results comparable to traditional 21-day oral regimen (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - May 8, 2018 Category: Primary Care Source Type: news
The Drugs That Changed Our Minds by Lauren Slater – review
Twenty years after hailing antidepressants in her memoir Prozac Diary, a now jaded, sceptical Lauren Slater revisits the psychopharmacological industry – with uneven resultsInProzac Diary (1998), Lauren Slater wrote powerfully of the way fluoxetine had transformed her previously chaotic life. While the author recorded a handful of negative side-effects – a profound loss of libido, for instance – the reader was left with the sense that Prozac had pieced back together the shards of Slater’s existence. In some ways,The Drugs That Changed Our Minds is a sequel to that book. Slater is now in her mid-50s, recently divorc...
Source: Guardian Unlimited Science - April 1, 2018 Category: Science Authors: Alex Preston Tags: Autobiography and memoir Science and nature Books Medical research Depression Society Culture Source Type: news
Proteus CMO talks regulation hurdles, future plans for digital pill
It ’s still the early days, but the FDA’s approval of Proteus Digital Health and Otsuka Pharmaceuticals’ Abilify MyCite has changed the discussion of digital technology in healthcare. (Source: mobihealthnews)
Source: mobihealthnews - March 8, 2018 Category: Information Technology Source Type: news
